The Cooper Companies, Inc. $COO Shares Sold by CW Advisors LLC

CW Advisors LLC lowered its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 11.3% in the second quarter, HoldingsChannel.com reports. The fund owned 140,687 shares of the medical device company’s stock after selling 17,937 shares during the quarter. CW Advisors LLC’s holdings in Cooper Companies were worth $10,011,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of COO. Zions Bancorporation National Association UT acquired a new position in shares of Cooper Companies during the 1st quarter worth approximately $33,000. J.Safra Asset Management Corp increased its position in Cooper Companies by 204.8% during the second quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock worth $36,000 after buying an additional 340 shares in the last quarter. GKV Capital Management Co. Inc. acquired a new position in shares of Cooper Companies in the first quarter worth $40,000. Assetmark Inc. lifted its position in shares of Cooper Companies by 357.8% in the second quarter. Assetmark Inc. now owns 618 shares of the medical device company’s stock valued at $44,000 after acquiring an additional 483 shares in the last quarter. Finally, Allworth Financial LP lifted its position in shares of Cooper Companies by 36.6% in the second quarter. Allworth Financial LP now owns 959 shares of the medical device company’s stock valued at $68,000 after acquiring an additional 257 shares in the last quarter. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently commented on COO. Needham & Company LLC reiterated a “buy” rating and set a $94.00 price objective on shares of Cooper Companies in a research report on Thursday, August 28th. Wells Fargo & Company reiterated an “equal weight” rating and set a $72.00 price target on shares of Cooper Companies in a report on Thursday, November 13th. Weiss Ratings reissued a “hold (c-)” rating on shares of Cooper Companies in a research note on Monday. JPMorgan Chase & Co. decreased their target price on shares of Cooper Companies from $76.00 to $66.00 and set a “neutral” rating on the stock in a research report on Thursday, August 28th. Finally, The Goldman Sachs Group set a $64.00 price target on Cooper Companies and gave the company a “sell” rating in a report on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $84.77.

Cooper Companies Price Performance

COO opened at $77.03 on Friday. The Cooper Companies, Inc. has a 1 year low of $61.78 and a 1 year high of $104.47. The company’s 50 day simple moving average is $72.01 and its 200 day simple moving average is $71.74. The stock has a market capitalization of $15.31 billion, a PE ratio of 37.95, a P/E/G ratio of 1.87 and a beta of 1.05. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 2.12.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.11 by $0.04. The company had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.06 billion. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. Cooper Companies’s revenue was up 4.6% on a year-over-year basis. During the same quarter last year, the firm posted $1.04 earnings per share. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. As a group, sell-side analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies declared that its board has approved a share repurchase program on Wednesday, September 17th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical device company to repurchase up to 15.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board of directors believes its stock is undervalued.

Insider Buying and Selling at Cooper Companies

In other news, Director Lawrence Erik Kurzius bought 2,000 shares of Cooper Companies stock in a transaction that occurred on Monday, September 29th. The shares were purchased at an average price of $68.39 per share, for a total transaction of $136,780.00. Following the completion of the acquisition, the director owned 5,777 shares of the company’s stock, valued at $395,089.03. The trade was a 52.95% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.98% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.